Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...
In the evolving landscape of metastatic colorectal cancer, managing patients with RAS/BRAF wild-type tumors remains a ...
81.8% ORR by BICR and 63.6% confirmed ORR by BICR at the 240 mg dose; 46.2% confirmed ORR in CNS Metastases 90.9% (n = 20/22) of patients with confirmed responses remained on study with a median ...
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--A pooled analysis of the TROPION-Lung05 phase 2 and the TROPION-Lung01 phase 3 trials showed datopotamab deruxtecan (Dato-DXd) demonstrated clinically ...
Approval is based on results from the Phase 3 PAPILLON study, which demonstrated RYBREVANT® plus chemotherapy reduced the risk of disease progression or death by 61 percent versus chemotherapy alone ...
Rybrevant plus Lazcluze, compared with Tagrisso, showed a trend towards favorable overall survival in EGFR-positive advanced non-small cell lung cancer. In the first line of treatment, Rybrevant ...
Savolitinib and osimertinib combination significantly improves PFS in EGFR-mutated NSCLC with MET amplification compared to ...
The European Commission has approved Tagrisso (osimertinib; AstraZeneca) combined with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced epidermal ...
Chemotherapy-free combination regimen ushers in new era for first-line treatment, with overall survival projected to exceed four years, surpassing monotherapy TKI osimertinib by more than one year ...
Chinese pharma Hansoh Pharma (HKEX: 3692) has secured approval from China’s National Medical Products Administration for an expanded use of its EGFR inhibitor Ameile (almonertinib). The decision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results